PET Imaging in Patients at Risk for Acute Lung Injury
NCT01486342 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5
Last updated 2013-01-04
Summary
Despite decades of research, the mortality in acute lung injury remains very high and treatment options are very limited. Given these facts, the best treatment modality may be in prevention of this lethal syndrome.
Historically, imaging has played a crucial role in understanding ALI. The appearance of chest radiography is one of the consensus criteria in defining ALI, and commuted tomography (CT) scans further advanced the understanding of the pathoanatomy of ALI. While valuable, these imaging modalities are nonspecific and do not incorporate functional cellular physiology.
PET imaging measures concentrations of radioisotopes in the body. By embedding in, but not altering molecules, the natural fate of these tracers can be studied with PET imaging. Advances in the understanding of ALI include blood flow distribution, as well as the response to alveolar recruitment maneuvers and prone positioning. Not all patients who are receiving mechanical ventilation develop ALI. Inflammation in the lungs is known to play a key early role in the development and progression of ALI. Secondary to inflammation, the lungs develop edema and do not exchange oxygen as well. This early inflammation is in part driven by a specific type of immune cell called the neutrophil. These cells seem to travel and become sequestered in the lung- they are "recruited" to the lung during this inflammatory stage. When there, these neutrophils release inflammatory substances which are integral in the development of ALI. Neutrophils use primarily glucose as a fuel source. The radio isotope \[18F\]Fluorodeoxyglucose (FDG)is a glucose analog and therefore taken up/ingested by the neutrophils as a part of their normal metabolism. Because of this fact, positron emission tomography (PET) using the radio isotope \[18F\]FDG is a highly sensitive marker to look at the recruitment of neutrophils to the lung, therefore quantifying the degree of pulmonary inflammation prior to the development of ALI.
The investigators seek to examine the relationship of pulmonary inflammation in patients at risk for ALI, but without clinical evidence of the syndrome. The investigators seek to enroll ten patients in a pilot trial.
Conditions
- Acute Lung Injury
- Early Pulmonary Neutrophilic Inflammation
Interventions
- RADIATION
-
PET-CT scan
PET-CT imaging with \[18F\]FDG will be performed within 24 hours of admission to the ICU. All patients imaged will be those remaining on mechanical ventilation at the time of PET imaging. A low-dose CT scan (50 effective mAs) will be obtained with placement of the participant such that the lungs are centered within the field of view. After completing the transmission scan, 10 mCi of \[18F\]FDG will be injected intravenously at the start of a 60-minute dynamic scan acquisition and the intravenous (IV) catheter flushed with 10 ml saline. Imaging will be obtained with the following framing schedule: 24 5-sec, 6 3-minute and 8 5-minute frames.
Sponsors & Collaborators
-
Washington University School of Medicine
lead OTHER
Principal Investigators
-
Brian Fuller, MD · Washington University School of Medicine
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-10-31
- Primary Completion
- 2012-10-31
- Completion
- 2012-10-31
Countries
- United States
Study Locations
More Related Trials
-
PET Assessment of Acute Lung Transplant Rejection
NCT02204202 ·Status: TERMINATED
-
The Utility of FDG-PET for Radiation Treatment in NSCLC
NCT00385164 ·Status: UNKNOWN
-
FDG-PET/CT for Simulation and Radiation Treatment Planning of Early Breast Cancer
NCT01432002 ·Status: UNKNOWN
-
Study of the Fixation of Various Vectors in PET/CT in Patients With a With Lung Cancer Before and During of CRT or RT
NCT01261585 ·Status: COMPLETED
-
Multi-Tracer Positron Emission Tomography in Patients With Solid Tumors
NCT01243333 ·Status: TERMINATED ·Phase: NA
-
Application of 68Ga NEB PET Imaging in the Diagnosis and Evaluation of Lymphatic Disorders
NCT04273334 ·Status: UNKNOWN ·Phase: PHASE1
-
Fluorine-18-α-Methyltyrosine Positron Emission Tomography for Diagnosis and Staging of Lung Cancer
NCT00464282 ·Status: COMPLETED
-
Influence of PET/CT Radiomic Features on the Outcome of Lung Cancer Patients
NCT03648151 ·Status: COMPLETED
-
PET CT Re-Planning NSCLC (4DCT-PET)
NCT03403127 ·Status: COMPLETED ·Phase: NA
-
[18F]F-AraG/Total Body PET Imaging and Healthy Subjects and Lung Cancer Patients
NCT04678440 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Benefits Study of Respiratory-gated PET Acquisition in Lung Disease
NCT01812031 ·Status: COMPLETED ·Phase: NA
-
Positron Emission Tomography for Detecting Non-small Cell Lung Cancer
NCT00004138 ·Status: COMPLETED ·Phase: NA
-
Breast PET Feasibility
NCT03198442 ·Status: COMPLETED ·Phase: NA
-
PET Imaging CCR2 in Lung Inflammation
NCT03492762 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
18F-FDS PET/CT in Healthy Volunteers and Patients With Suspected Infection
NCT02450942 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Fludeoxyglucose F-18-PET in Planning Lung Cancer Radiation Therapy
NCT03493789 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of 11C-acetate PET Imaging as a Novel Approach to Detecting Pathology in Pulmonary TB
NCT02972697 ·Status: UNKNOWN ·Phase: PHASE1
-
18F-FDG Uptake Measurements in Malignant Solid Tumors on PET/CT and PET/MR
NCT02717572 ·Status: COMPLETED ·Phase: PHASE1
-
The Role of 18F-FDG-PET/CT Scan in Lung Cancer Patients
NCT04395651 ·Status: UNKNOWN
-
The Beneficial Value of PET/CT in the Follow-up of Stage III Non-small Cell Lung Cancer Patients
NCT06082492 ·Status: RECRUITING ·Phase: NA
-
Added Value of PET/CT in Lung Cancer
NCT06494800 ·Status: NOT_YET_RECRUITING
-
Evaluation of Attenuation Correction Accuracy in Positron Emission Tomography-Magnetic Resonance Imaging (PET-MRI)
NCT03423407 ·Status: TERMINATED
-
PET-DECT for Staging and Imaged Based Radiotherapy Planning in Lung Cancer
NCT03146117 ·Status: TERMINATED
-
Fluorine-18-α-Methyltyrosine Positron Emission Tomography (18F-FMT PET) for Therapy Response in Lung Cancer
NCT00826033 ·Status: COMPLETED
-
Lung Nodule Detection Using Ultra-long FOV PET/CT
NCT05463913 ·Status: RECRUITING ·Phase: PHASE4